Cancer Biopsy Market Segmentation:
Cancer Type (Breast, Colorectal, Stomach, Lung, Liver, Prostrate, Ovarian, And Other Cancer Types)
In cancer type, the breast cancer segment in the cancer biopsy market is projected to register the highest share of 21.1% by the end of 2035. According to the American Cancer Society, 310,720 new cases of invasive breast cancer are projected to be diagnosed in women in 2024, causing as many as 42,250 deaths, among women. It further predicts that nearly 2,790 men will also be diagnosed with breast cancer by the end of 2024, registering approximately 530 deaths from the disease. Owing to the rising amount of breast cancers especially among women, the segment is anticipated to garner the highest growth rate in the upcoming years, in the cancer biopsy market.
End user (Hospitals, Cancer Research Centers, Diagnostic Centers, and Research and Academics)
Hospitals are projected to dominate the end user segment primarily due to their comprehensive healthcare services and advanced diagnostic capabilities. The hospitals are equipped with state-of-the-art imaging and laboratory facilities, facilitating a wide range of biopsy procedures, including surgical and minimally invasive techniques. The increasing number of cancer cases and the need for timely diagnosis and treatment further strengthen hospital’s positions as primary providers of biopsy services. As healthcare continues to evolve, hospitals are likely to remain at the forefront of the cancer biopsy market.
Our in-depth analysis of the cancer biopsy market includes the following segments:
|
Biopsy Type |
|
|
Products & Services |
|
|
Cancer Type |
|
|
End user |
|
